As described elsewhere in this special issue, substantial progress has been made over the past 60 years with regard to characterizing the basic pathophysiology of epilepsy, developing new therapies, recognizing the psychiatric comorbidities of epilepsy, identifying determinants of felt and enacted stigma, and disseminating information about epilepsy to professionals and the lay public.
1.
What are the problems with the clinical and social management of epilepsy today?
Diagnosis. The diagnosis of epilepsy today is largely based on clinical grounds and supported by diagnostic tests, primarily electroencephalography (EEG) and neuroimaging studies. 1 Notwithstanding significant advances in EEG and neuroimaging techniques, there remain multiple diagnostic challenges to the evaluation of persons at risk for developing epilepsy as well as those with epilepsy. At the present time, we are unable to accurately identify persons before they manifest seizures determine which patients, having had one seizure, are certain to have further seizures and which patients will definitely not specify which antiepileptic drug (AED) or AED combination is most likely to effectively and safely prevent seizures in a given PWE avoid potentially life-threatening, idiosyncratic reactions to AEDs, with the notable exception of carbamazepine 2 decide when AEDs can be discontinued without risk of seizure recurrence
Because diagnostic tests to support these everyday clinical decisions are not available, patients may be unnecessarily exposed to AEDs, whether to prevent a first seizure or subsequent seizures, or may unnecessarily suffer from seizures and the associated physical and psychiatric complications as well as the social ramifications.
Another limitation at present is that many epilepsy comorbidities, such as mood or psychotic disorders, reproductive endocrine disorders and nonepileptic attack disorder (also called psychogenic While substantial progress over the past 60 years has enabled a greater proportion of persons with epilepsy (PWE) to live without seizures and treatment-related side effects, numerous challenges in the diagnosis, treatment and social management of epilepsy remain to be solved over the next 60 years so that no person with epilepsy is limited by any aspect of the condition. This achievement is within our reach, but will require professional and lay epilepsy organisations to work closely together to ensure that clinical, scientific and sociological advances are made and applied to the medical and social management of epilepsy.
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nonepileptic seizures) cannot be accurately diagnosed, especially prior to or soon after becoming clinically symptomatic. Consequently, diagnosis and initiation of treatment for these conditions is often delayed months to years. 3, 4 A fundamental diagnostic problem pertains to measurement of seizures -the primary symptom of epilepsy. Indeed, the treatment of PWE and the assessment of new interventions with clinical trials are based on quantifying seizure frequency and severity. Patient and caregiver self-report, for example with a diary, is the typical means for gauging the frequency and severity of seizures. However, self-report has been shown to be inaccurate, which compromises the extent to which treatments can be optimized or fully assessed for effectiveness. 5 Treatment. Treatment is typically begun after seizures become manifest and the determination is made that additional seizures are likely. 1 The goals of treatment are to address the underlying cause, if known, and achieve seizure freedom without troublesome AED-related side effects. Seizure type, epilepsy syndrome, and demographic variables such as age, gender and concomitant medications are used to select an initial AED. Despite the introduction of an unprecedented number of new AEDs and as well as non-pharmacological treatments over the past 15 years, as many as two out of every three PWE with access to therapies experience incomplete seizure control or AED-related side effects that diminish their quality of life. Furthermore, inexpensive, effective, safe, well-tolerated and culturally acceptable treatments that can be reliably and continuously distributed to the tens of millions of PWE impacted by the treatment gap in resource-poor regions around the world are not readily available.
Other significant challenges to the effective treatment of PWE include our current inability to:
individualize the selection of AEDs based, for example, on genetic makeup or biomarkers that indicate the precise pathophysiological disturbance(s) underlying seizures, assuming that such exists prevent the development of epilepsy in patients at high risk, including patients with genetic predisposition and those with risk factors such as tumours, traumatic brain injury, stroke, major depression or ADHD 6 Persons with epilepsy whose seizures do not respond to the first and second appropriately chosen and dosed AEDs as monotherapy are candidates for combinations of AEDs. At present, however, we cannot individualize the selection of AED combinations for a specific patient any more than we can individualize AED monotherapy. Patients with drug-resistant epilepsy 7 may be candidates for adjunctive nonpharmacological treatments such as resective brain surgery, vagus nerve stimulation, special diets, and stress reduction techniques; as well as for investigational drugs and brain stimulation devices. However, other than for resective surgery, we do not have biomarkers that predict a successful outcome for these interventions. Furthermore, access to care, costs, and other factors may present insurmountable barriers to obtaining these non-pharmacological treatments.
Research efforts as well as the advocacy efforts of numerous epilepsy organisations over the past 60 years have increasingly focused on patients with drug-resistant seizures, who are at increased risk of mood disorders, injuries, death and the potentially disabling psychosocial consequences of epilepsy, but these remain largely unsolved problems. Yet while the control of seizures has been the primary objective in the care of PWE and related research initiatives over the past 60 years, and appropriately so, a large proportion of PWE experience an unsatisfactory quality of life because of other factors, such as treatment-related side effects, cognitive dysfunction, stigma, the post-ictal state, and psychiatric disorders, including depression and anxiety. 8 Available evidence-based therapeutic options for these non-ictal aspects of epilepsy are limited and further compounded by inadequate diagnostic methods as noted earlier.
Many patients with drug-resistant seizures as well as a significant proportion of PWE who achieve seizure freedom have troublesome dose-related AED side effects or idiosyncratic organ toxicity, in part because the current approach to treatment is to administer therapies orally and at dosages and dosing intervals that maintain constant serum therapeutic levels. As a result, systemic structures such as bone marrow, liver and skin, as well as areas of the brain unrelated to seizure control, are continuously exposed to the potentially toxic effects of AEDs, even though seizure-suppressing treatments may actually be needed only intermittently to prevent seizures and directed only to specific targets in the brain.
In resource-constrained areas, a large proportion of PWE receive no evidenced-based treatment. Further compounding this deplorable situation is that PWE from these regions are often highly stigmatized. 9 Social management. The tremendous progress in the social management of epilepsy achieved over the past 60 years has made it possible for more PWE than ever before to live at their full potential. 10 However, epilepsy continues to present unique challenges to the large majority of PWE and their families, including uncertainty and fear of having a seizure; limitations on lifestyle, school, driving and employment; cognitive impairment; lack of seizure control and treatment-related side effects. 11, 12 In developed countries, the care of PWE is largely provided by physicians and allied health personnel in clinics based on an acute care model. In such settings, the comprehensive needs of PWE and their families are generally not addressed, in contrast to the more holistic approach made possible by a chronic care model. 13, 14 As a result, issues pertaining to behaviour, mood, medication adherence, schooling, employment, transportation, insurance, exercise, socialization, and alternative treatments, to name a few, may be unrecognized or remain unresolved, thereby exacerbating the underlying issues, increasing stress levels, and further complicating the control of seizures, comorbidities and AED-related side effects.
2. What should be the goals of clinical and social management of epilepsy for the next 60 years?
The scientific, medical and social advances of the past 60 years have brought us closer to meeting today's goals of ''no seizures, no side effects'' for PWE who have access to knowledgeable clinicians and appropriate diagnostic tests and treatments. Over the next 60 years, the global epilepsy community should dedicate its efforts to enable all PWE and persons at risk for developing epilepsy, irrespective of their ethnic background, financial means or where they live, to achieve their full potential, unburdened by the physical, psychological and social consequences of epilepsy that remain life-limiting to many today, thereby expanding the goals to ''no seizures, no side effects, no comorbidities, no stigma''; in short, no limitations because of epilepsy.
Making significant progress will require the scientific and lay epilepsy organisations to work together to pursue collectively agreed upon benchmarks [http://www.ninds.nih.gov/research/ epilepsyweb/2007_benchmarks.htm]; challenge commonly held concepts; expand the pre-clinical models of epilepsy; improve upon the available methods for diagnosis and treatment of epilepsy and comorbidities; fully delineate and address the root causes of the global treatment gap; and put into place a comprehensive evidence-based plan to eliminate felt and enacted stigma. 15, 16 Increasing knowledge, and changing attitudes and perceptions about epilepsy. Eliminating stigma and improving access to appropriate medical care will require a significant increase in the ongoing efforts to provide educational programs for the very youngest in elementary schools through students at health-related graduate schools, and to all relevant groups of people, including PWE, their family members, health professionals, community leaders, employers, policymakers, teachers, and first responders. Electronic dissemination of information should take advantage of social networking tools when appropriate. Research should help define the best methods for delivering this knowledge to achieve the desired impact on the attitudes and perceptions of the target groups.
Establishing new models for the delivery of medical and psychosocial care. New models of delivering health care to PWE, facilitated by linkages between patients, care providers, electronic medical records, and medical devices, for example wearable technology to detect seizures, should be explored and compared with current models. Such approaches could include combining primary and speciality care 17 ; internet-facilitated remote care for PWE who cannot travel to care providers, as demonstrated by a recent study for the treatment of depression 18 ; and partnering with local healers in resource-poor environments.
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Diagnosis. Given the inaccuracy of self-report for seizure frequency and severity, and the low specificity and sensitivity of diagnostic tests, which even under the best of circumstances cannot predict with certainty which AED would fully control seizures, we need new biomarkers for patients presenting after their first possible seizure that confirm the patient will have further seizures and that provide the basis for an individualized treatment plan that will completely suppress seizures without side effects. 20 These biomarkers are unlikely to emerge from a single laboratory, but rather a massive effort to link together researchers, clinicians, the major funding agencies, such as NIH, and industry, as was done successfully for Alzheimer's disease [http://www.nih. gov/news/health/mar2009/nia-17.htm]. Until we have the cure for all forms of epilepsy, those patients whose seizures cannot be fully controlled may benefit from technologies that accurately predict the likelihood of an impending seizure and provide a warning sufficiently in advance of a seizure for the PWE or caregiver to administer an abortive therapy or take steps to reduce the likelihood of injury. 21 Seizureprediction and -detection systems can also be coupled with treatments such as brain stimulation or local drug delivery in a closed-loop, automated fashion, and also transmit EEG patterns and other physiological signals to physicians and electronic medical records as a tool to monitor clinical response to treatments. 22 These technologies and others that improve upon the accuracy of patient self-report and enhance patient safety or reduce the impact of seizures should be designed to augment the PWE's sense of mastery and self-empowerment and not to inadvertently contribute to felt or enacted stigma, as anticipated by the painting shown in Fig. 1 .
The diagnostic challenges associated with caring for PWE who live in resource-constrained environments or far from medical facilities could be facilitated by internet-based communications as well as portable diagnostic equipment that could be sent to the patient, such as an EEG recorder with easy-toapply electrodes, that would then be mailed back for analysis after use.
Finally, new techniques are needed to accurately diagnose the precise underlying cause(s) of cognitive disturbances, such as memory dysfunction, behavioural and mood disorders, and dysfunctional social adaptation so that appropriate interventions can be developed and made available for the care of PWE. 23 Treatment. As the pathophysiology of seizures, epileptogenesis and drug-resistant epilepsy are further elucidated and conceptual models advance, novel therapeutic targets will be identified and incorporated into new laboratory-based models of epilepsy. Compounds that interact with these targets and show benefit in animal models would be candidates for further preclinical and clinical testing to assess their efficacy and safety as treatments to prevent the development of epilepsy in patients at high risk and to achieve seizure freedom for newly treated patients and those with drug-resistant epilepsy. However, the costs of drug development in epilepsy have significantly escalated. If these trends continue, it will become increasingly less likely that drugs will be developed principally for the treatment of epilepsy. Therefore, the epilepsy community should work together to lower costs of bringing new treatments to the market, where possible, especially therapies intended for specific epilepsy syndromes.
Given the many unmet needs discussed earlier, other goals that should be pursued over the next 60 years include:
Empowering PWE to become active partners in managing their health Expanding the access of PWE to epilepsy surgery Developing safe and effective behavioural techniques to avoid and terminate seizures, as well as to reduce stress and the severity of anxiety and depressive symptoms Identifying biomarkers that allow for rational AED use; including selection of AEDs and dosages and the identification of which patients should be treated after the first seizure and which patients can be safely taken off treatment without seizure recurrence Avoiding the development of interictal mood, behavioural and psychotic disorders Preventing accidental death, sudden and unexplained death in epilepsy (SUDEP), status epilepticus, and suicide Targeting the precise cause(s) of a patient's memory and cognitive problems with effective interventions Developing effective treatments for the psychological problems underlying psychogenic seizures in PWE Establishing affordable, culturally acceptable and sustainable therapies to address the global treatment gap Best practices for the medical and social management of epilepsy in resource-constrained areas are under increasing study and various stages of implementation through large-scale initiatives such as the WHO/ILAE Global Campaign Against Epilepsy. 24 Generally, these initiatives target the treatment gap as well as the development of skilled diagnostic and treatment services, the amelioration of stigma, and the dissemination of information to enhance knowledge and positive attitudes about epilepsy among key stakeholders, such as laypersons, teachers, professionals, first responders and clergy. It is critical for these efforts to continue and significantly grow in scope.
The roles of social agencies. As the main societal voice for PWE and their families, organisations such as Epilepsy Action have become change agents for improving the quality of life for PWE. Increasing the public's awareness about epilepsy; educating all key stakeholders about epilepsy, and its treatment and consequences; providing advice and referral, and in some cases, legal representation; allocating funds for research, particularly regarding the psychosocial aspects of epilepsy; and working with government bodies to protect the rights of PWE are all vitally important functions that need to expand.
The roles of social agencies will be increasingly important over the next 60 years as the pressure increases to reduce government healthcare expenditures as a percentage of overall spending and as more and better organised healthcare agencies vie for limited government research dollars and public philanthropic support. To ensure that progress continues to be made in spite of these trends, professional and lay epilepsy organisations worldwide should work closely together to ensure that the medical and social management of epilepsy evolves together with advances in medical science to achieve a world in which no PWE is compromised by epilepsy. 20 
